Advances in Cancer Research
- 1st Edition, Volume 98 - February 16, 2014
- Latest edition
- Editors: George F. Vande Woude, George Klein
- Language: English
The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. A very special event the Nobel Minisy… Read more
The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. A very special event the Nobel Minisymposium, “Molecular Oncology – From Bench to Bedside,” held at the Karolinska Instituet, in Stockholm, Sweden, was marked the celebration of George and Eva Klein’s combined 160th birthday. To honor this occasion, this 2nd of two volumes brings together contributions by their former students, colleagues and collaborators of the past fifty years into a volume of Advances in Cancer Research dedicated to George and Eva. Over a decade ago, a subdivision of ACR called “Foundations in Cancer Research” was initiated and the tributes honoring the Kleins’ bodies of work presented at the minisymposium are especially appropriate for the series.
Researchers and students in the basic and clinical science of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology and molecular biology.
- Contributors
- Publisher Summary
- Why Do We Not All Die of Cancer at an Early Age?
- Abstract
- I Introduction
- II Immune Surveillance
- III Genetic Surveillance (DNA Repair)
- IV Intracellular Surveillance
- V Is There Epigenetic Surveillance?
- VI Intercellular Surveillance
- VII Summary
- Acknowledgments
- The Early History of Plasma Cell Tumors in Mice, 1954–1976†
- Abstract
- I Introduction
- II Plasma Cells Before the 1950s: Discovery, Uncertain Origins
- III Multiple Myeloma
- IV Abnormal Protein
- V New Ideas About the Cellular Basis of Antibody Formation in the 1950s
- VI First PCTs in Mice
- VII Lloyd Law’s Suggestion
- VIII X5563 and X5647
- IX Specific Induction of PCTs in Mice by Implanting Millipore Diffusion Chambers: Ruth Merwin and Thelma Dunn
- X Mineral Oil and the Hyperimmunization Hypothesis
- XI Discoveries on Antibody Structure Using Human Myeloma Proteins Changed the Course of Immunology, 1961–1965
- XII Enter Mel Cohn
- XIII Pneumococcal Type C Polysaccharide (PnC) and Phosphorylcholine
- XIV Herman Eisen, DNP, and MOPC315
- XV Irrelevant and Relevant Antigens
- XVI The Antidextrans, Antilevans, and Antigalactans
- XVII Growing PCTs in Culture and Growth Factors
- Acknowledgments
- Mouse Mammary Tumor Biology: A Short History
- Abstract
- I Introduction
- II The Dawning of Experimental Cancer Research
- III Mendelian Mouse Genetics: 1909–1920
- IV The Inbred Mouse in Mouse Mammary Tumorigenesis: 1920–19303
- V The Extrachromosomal Factor: 1933–1940
- VI The Milk Agent 1936–1970
- VII MMTV and the Rise of Tumor Immunology
- VIII Hormones and the Emergence of Endocrinology
- IX The National Cancer Institute and the Birth of Molecular Biology: 1970–1980
- X Neoplastic Progression: 1954
- XI Neoplastic Progression: 1959 the HAN
- XII Genetically Engineered Mice: 1984–2006
- XIII Epilog
- Acknowledgments
- Ordered Heterogeneity and Its Decline in Cancer and Aging
- Abstract
- I Introduction
- II The Role of Tissue Size in Developmental Biology
- III Behavior of Dissociated Cells and Their Reassociation
- IV The Molecular Basis of Cell–Cell Adhesion
- V Contact Relations Among Homophilic Cells in Regulation of Growth and Proliferation
- VI Role of the Plasma Membrane in the Regulation of Cell Growth
- VII Normalization of Neoplastic Cells by Contact with Normal Cells
- VIII Concluding Remarks
- Acknowledgments
- Reversal of Tumor Resistance to Apoptotic Stimuli by Alteration of Membrane Fluidity: Therapeutic Implications
- Abstract
- I Introduction
- II Membrane Structure and Dynamics
- III Involvement of Physicochemical Properties of the Plasma Membrane in Cellular Functions of Normal and Tumor Cells
- IV Membrane Fluidity and Apoptosis
- V Membrane Fluidity and Cancer
- VI Membrane Fluidity in Cancer Therapy
- VII Modulation of Multidrug Resistance by Alterations of Membrane Fluidity
- VIII Therapeutic Interventions and Novel Approaches in Cancer Therapy
- IX Concluding Remarks
- Acknowledgments
- Mutant Transcription Factors and Tyrosine Kinases as Therapeutic Targets for Leukemias: From Acute Promyelocytic Leukemia to Chronic Myeloid Leukemia and Beyond
- Abstract
- I Introduction
- II PML‐RARα as a Therapeutic Target for Differentiation Therapy
- III Tyrosine Kinases as Target for Apoptosis Induction Therapy
- IV Perspectives
- Acknowledgments
- The Effect of Cell–Matrix Interactions and Aging on the Malignant Process
- Abstract
- I Introduction
- II The Extracellular Matrix
- III Age‐Dependent Changes of Tissues
- IV Cell–Matrix Interactions
- V Role of Proteolytic Enzymes and ROS
- VI The Elastin‐Laminin Receptor
- VII Modifications of ECM‐Patterning by the Neoplastic Process
- VIII Role of ECM Macromolecules
- IX Effect of Cell‐Aging and of Modified Cell–Matrix Interactions on the Malignant Process
- X Signaling by ECM Macromolecules and Their Proteolytic Fragments
- XI Concluding Remarks
- Note Added in Proof
- Acknowledgments
- Index
- Publisher Summary
- Edition: 1
- Latest edition
- Volume: 98
- Published: February 16, 2014
- Language: English
GV
George F. Vande Woude
Affiliations and expertise
Director, Van Andel Research Institute, Grand Rapids, MI, USA
NCI-Frederick Cancer Research Facility Frederick, Maryland
ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, Frederick, MarylandGK
George Klein
Affiliations and expertise
Karolinska Insitutet, Stockholm, SwedenRead Advances in Cancer Research on ScienceDirect